MIBELLE BIOCHEMISTRY

Mibelle Biochemistry designs and develops unique, high-quality active ingredients for the cosmetics industry, based on natural substances and high scientific expertise.

This independent business unit within the Mibelle Group was founded in 1995 by Dr Fred Zülli in Buchs, Switzerland.

In a short period of time, Mibelle Biochemistry has built an excellent reputation worldwide as a creator of innovative active ingredient concepts and a true expert in the fields of biotechnology and biochemistry. Its wide range of active ingredients is available in over 50 countries worldwide.

Our slogan "Inspired by nature - Realized by science" reflects our philosophy.

Our experts transform natural plant compounds into bioactive cosmetic ingredients. Our R&D team uses encapsulation technologies that guarantee optimal bioavailability and thus ensure maximum effectiveness of the active ingredients.

Commitment to sustainable development is at the heart of our business and continues to grow.

Visio-Conference Biomim'SCOPE, BIOMIMÉTISME ... & COSMÉTIQUE - Review of trends, news and prospects, and presentation of the latest bio-inspired innovations by Mibelle. With Vincent Briffaut, Sales Director France, and Stéphane Poigny, R&D Director France, Mibelle Biochemistry France.

BIOTECHNOLOGIES AND BIO-INSPIRATION OR THE FUTURE OF THE COSMETIC REVOLUTION. Vincent Briffaut interviewed by Nicolas Doze on BFM BUSINESS.

More on the website


Contact:

Vincent BRIFFAUT
Sales Director France

Mibelle Group Biochemistry | Mibelle AG | 17-21 Rue St Fiacre | 75002 Paris | France

Tel +33 1 73 06 23 43

AMSILK, the spider silk

AMSilk produces and distributes increasing volumes of high-quality silk biopolymers for use in textile products, medical devices and cosmetics.
One of the most amazing and revolutionary bio-inspired innovation. Now available with a wide range of applications : footwear, apparel, technical textiles, fashion, automotive, aviation ...
For subscribers

MYCOPHYTO

MYCOPHYTO was co-founded in 2017 by Justine LIPUMA, a doctor in microbiology, and Christine PONCET, an agricultural engineer. Spin off INRAE (INRA) and UCA (Université Côte d'Azur), it has received more than 12 awards since its creation.

MYCOPHYTO is to develop, produce and propose to agricultural professionals effective biological solutions by adapting scientific knowledge concerning mycorrhizal symbiosis.

MYCOPHYTO, an INRAE and UCA spin-off, integrates the latest knowledge from life sciences and technological innovations. The start-up has patented solutions for the implementation of native arbuscular mycorrhizal fungi (AMFs) in crops to recreate sustainable natural synergies with plant roots.

MYCOPHYTO is based on a dynamic of key players including: world-renowned scientists, joint research structures, technical and training institutes and farmer ambassadors.


Videos :


Other releases :

LA TRIBUNE / 18 MAR 2020 / Mycophyto, the proof-of-concept deeptech

BPI FRANCE / 19 NOV 2019 / Mycophyto: Agriculture transformed by science

HORIZONS / 17 DEC 2019 / Mycophyto, the natural alternative to pesticides that increases yields

CREDIT AGRICOLE INFO / 21 OCT 2019 / Mycophyto, a natural and tailor-made alternative to chemical inputs

FRENCH WEB / 25 SEP 2019 / Startup Mycophyto raises €1.4 million to offer an organic alternative to pesticides


Website


Contact:

Justine LIPUMA, Co-Founder & CEO
540 avenue de la Plaine
06250 Mougins
contact@mycophyto.fr

CHIMECO

The Bio-inspired Chemistry and Ecological Innovations laboratory, known as ChimEco, brings together researchers and engineers from the CNRS and a teacher-researcher from the University of Montpellier. As its activities are highly valued by industry, half of the researchers are financed by industrial contracts. The ChimEco laboratory is located in the Cap Delta business centre in the Montpellier agglomeration, in the heart of the Euromedicine park biopole.

The ambitions of the ChimEco laboratory are to develop an interdisciplinary approach to global ecology as a vector for sustainable development.

The unusual combination of phytotechnologies adapted to pollution, the ecological rehabilitation of degraded sites and the valorisation of these processes by an innovative and bio-inspired green chemistry, ecocatalysis, must contribute to the development of the current scientific, economic and environmental priorities of ecological innovation.


Claude Grison's speech at Biomim'expo 2017 :

The film Nature=Future:

TEDx 2015 :

Klorane Botanical Foundation - Mint, a plant that cleanses water:

The board Biomim'review :


The portrait page in the Biomim'BOOK 2019 :


Website

 

 

 

JOHNSON & JOHNSON

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.

Every day, our more than 130,000 employees across the world are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Aspiring Toward a Healthier World

We aspire to improve health in all we do and everywhere we go. Citizenship and sustainability have long been engrained in our culture, built on a foundational belief that a healthier planet offers benefits to human health.To ensure we live up to our commitments, we have a long legacy of goal setting, having established the first public goals in 1990. Our newly named Johnson & Johnson Health for Humanity 2020 Goals expanded how we think about health and we have sought out new ways to make everyone, everywhere, healthier.

We ensure people have access to better care around the world, make the places we live, work and play healthier by using fewer resources, and team up with partners and employees to further advance our culture of health and well-being.


The portrait page in the Biomim'BOOK 2019 :


Website


Contact:

Ayla Kiser, PhD

Senior Scientist in Biomimicry

Johnson & Johnson Santé Beauté France

Maigremont Campus

AKiser2@its.jnj.com

POLYNAT

POLYNAT, EXPERTISE IN ECO-DESIGN OF INNOVATIVE AND EFFICIENT BIO-BASED MATERIALS

Using the best of nature to eco-design the materials of tomorrow.

The search for alternatives to fossil fuels and the need to combat climate change are encouraging the development of new materials and more environmentally friendly chemistry.


Website


 

POLYMARIS BIOTECHNOLOGY

Polymaris Biotechnology is a biotechnology company founded in April 2008 by Anthony Courtois and Bertrand Thollas, who are convinced of the untapped riches of the ocean.

Polymaris has developed a solid and unique expertise in the research, characterisation and valorisation of innovative marine biomolecules, in particular bacterial exopolysaccharides.

These natural and biodegradable biomolecules are produced from a private and original collection of microorganisms taken from the immense marine biodiversity during numerous oceanographic campaigns.

Multidisciplinarity is a strength for Polymaris as it makes it a unique company responding to customised needs in the development and commercialisation of innovative marine biopolymers.

Since October 2011, Polymaris has been approved for the Research Tax Credit by the Ministry of Research.


The portrait page in the Biomim'BOOK 2021 :


Quoted in the Maddyness dossier: OceanTech, a promising field shunned by investors.

"We produce biodegradable sugars and plastics points out Anthony Courtois, President of Polymaris, who stresses that "marine biodiversity is greater than that of the terrestrial ecosystem . The leader believes that the company has "Generating a collection of microorganisms suitable for future industrial use . And there's plenty to do: the markets are varied, from cosmetics to medical devices to phytosanitary products. The startup, which was born in the Ifremer laboratories in Brest where its co-founders did their doctorate, says it did not need to raise funds to finance itself because it is making "of the turnover since the beginning of its activity".. However, the sector's own funding issues also resonate with her. "We could use financial partners to outsource certain activities. says Anthony Courtois, according to whom he "We need to trust small structures more"..


Website